AMCP Partnership forum: Managing care in the wave of precision medicine

Rachel Anhorn, Kristine Ashcraft, Mary Beattie, Elise Berliner, Kristine Bordenave, Patricia Bourne, Lena Chaihorsky, Mike Ciarametaro, Lisa Egbuonu-Davis, Matthew Feltman, Karen Geary, Stuart Goldberg, Nadia Haque, Lalymar Havern, Samuel Johnson, Julie Johnson, Summerpal Kahlon, Nicholas Keeling, Jill Kolesar, Laura KoontzErick Lin, Jay Mcknight, Kristen Migliaccio-Walle, Franziska Moeckel, Robert Pannone, David Parker, Chip Parkinson, Daryl Pritchard, Daryl Spinner, Robin Turpin, Jeffrey Waldron, Todd Winey, Caroline Huber

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Precision medicine, the customization of health care to an individual's genetic profile while accounting for biomarkers and lifestyle, has increasingly been adopted by health care stakeholders to guide the development of treatment options, improve treatment decision making, provide more patient-centered care, and better inform coverage and reimbursement decisions. Despite these benefits, key challenges prevent its broader use and adoption. On December 7-8, 2017, the Academy of Managed Care Pharmacy convened a group of stakeholders to discuss these challenges and provide recommendations to facilitate broader adoption and use of precision medicine across health care settings. These stakeholders represented the pharmaceutical industry, clinicians, patient advocacy, private payers, device manufacturers, health analytics, information technology, academia, and government agencies. Throughout the 2-day forum, participants discussed evidence requirements for precision medicine, including consistent ways to measure the utility and validity of precision medicine tests and therapies, limitations of traditional clinical trial designs, and limitations of value assessment framework methods. They also highlighted the challenges with evidence collection and data silos in precision medicine. Interoperability within and across health systems is hindering clinical advancements. Current medical coding systems also cannot account for the heterogeneity of many diseases, preventing health systems from having a complete understanding of their patient population to inform resource allocation. Challenges faced by payers, such as evidence limitations, to inform coverage and reimbursement decisions in precision medicine, as well as legal and regulatory barriers that inhibit more widespread data sharing, were also identified. While a broad range of perspectives was shared throughout the forum, participants reached consensus across 2 overarching areas. First, there is a greater need for common definitions, thresholds, and standards to guide evidence generation in precision medicine. Second, current information silos are preventing the sharing of valuable data. Collaboration among stakeholders is needed to support better information sharing, awareness, and education of precision medicine for patients. The recommendations brought forward by this diverse group of experts provide a set of solutions to spur widespread use and application of precision medicine. Taken together, successful adoption and use of precision medicine will require input and collaboration from all sectors of health care, especially patients.

Original languageEnglish
Pages (from-to)583-588
Number of pages6
JournalJournal of Managed Care and Specialty Pharmacy
Issue number7
StatePublished - Jul 1 2018

Bibliographical note

Publisher Copyright:
© 2018, Academy of Managed Care Pharmacy.

ASJC Scopus subject areas

  • Pharmacy
  • Pharmaceutical Science
  • Health Policy


Dive into the research topics of 'AMCP Partnership forum: Managing care in the wave of precision medicine'. Together they form a unique fingerprint.

Cite this